Phase 2 study of a Rift Valley fever vaccine for safety
Part of Digestive system, Infections clinical trials.
This study tests how safe a Rift Valley fever (RVF) vaccine is and how strongly it triggers the body’s immune response. You may be eligible if you are at risk of RVF exposure and your blood test shows you don’t already have strong protection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 65 years old when you sign consent
- Your RVF blood test must show low protection: PRNT80 under 1:10 for the main series, or under 1:40 for booster shots
- If you can become pregnant, you must have a urine pregnancy test the same day as each vaccine and agree not to get pregnant for 3 months after the last dose
- You must be at risk for RVF exposure and have submitted a request for the study vaccine through the IND process
- You must complete required screening and follow-up visits, including regular safety check-ins for at least 28 days after each dose
- You must agree to delay blood donation for 1 year after the vaccine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with fever or unexplained bleeding in East and Central Africa to learn more about illnesses like Rift Valley fever. By joining, you can help doctors understand and better treat these conditions.
This study tests a new vaccine, V4020, that may help protect against Venezuelan equine encephalitis (VEE), a rare but serious virus spread by mosquitoes. It is the first step in humans to see if it is safe and how the body responds.
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
This trial tests an experimental vaccine for respiratory syncytial virus (RSV), a common virus that can cause serious lung infections, especially in older adults. The study checks if the vaccine is safe and how the body responds to it.
This study tests an experimental vaccine to see if it is safe for healthy adults. The vaccine is made with mRNA technology and aims to protect against RSV, a common respiratory virus.
This trial tests a new vaccine against respiratory syncytial virus (RSV), a common virus that can cause lung infections. It is for healthy adults aged 18 and older, to see if the vaccine is safe and produces a good immune response.
Hear when a new Rift Valley Fever trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.